A new study published in The Lancet Microbe reports the first twice-yearly injectable HIV treatment regimen—combining lenacapavir, teropavimab, and zinlirvimab—has achieved high rates of viral ...

Add Yahoo as a preferred source to see more of our stories on Google. AUSTIN (KXAN) — Advocates for HIV prevention are calling a newly approved injectable medication a major step in eliminating the ...

Long-acting injectable CAB+RPV maintains high virologic suppression in patients with HIV and obesity, showing comparable real-world efficacy.

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

Nigeria has taken a major step in its fight against HIV with the arrival of the first tranche of lenacapavir, a long-acting injectable drug expected to transform HIV prevention and accelerate progress ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. NEW YORK (PIX11) — A new kind of HIV ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE - This colorized electron microscope image provided by the U.S. National Institutes of Health shows a human T cell, in blue, ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new long-lasting prophylactic treatment for HIV-1 that is administered once every 6 months. Lenacapavir (Yeytuo, Gilead ...

A twice-yearly injection described as the most promising HIV prevention tool in decades is poised to reach millions more people, with new generic versions priced at about $40 per patient per year. The ...

LONDON — The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which scientists say could help end the virus’ transmission. In a statement ...

Nigeria has received Lenacapavir, a twice-yearly HIV prevention injection, to expand prevention options and accelerate ...